文献速递糖尿病

六种生物标志物组合显著改善2型糖尿病预测:MONICA/KORA研究

A Panel of 6 Biomarkers Significantly Improves the Prediction of Type 2 Diabetes in the MONICA/KORA Study Population.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

基于MONICA/KORA人群的病例队列研究(发现集689例新发病例、1850例非病例;验证集262例新发病例、2549例非病例),在47种血清生物标志物中筛选出6种最相关标志物,将其同时加入非侵入性临床模型或临床模型+HbA1c后,均显著改善2型糖尿病预测性能(发现集C指数提升0.053,验证集提升0.034)。

要点

  • 六种生物标志物(IL-1Ra、IGFBP-2、sE-选择素、核心蛋白聚糖、脂联素、HDL-C)可显著提升预测。
  • 在非侵入性临床模型基础上加入六种标志物,发现集C指数提升0.053(95%CI 0.039-0.066)。
  • 在临床模型+HbA1c基础上加入六种标志物,两研究均见显著改善。

核心结论

  • 同时加入六种生物标志物可显著改善2型糖尿病预测,无论基于非侵入性临床模型还是临床模型联合HbA1c。

研究设计与样本

  • 基于人群的病例队列研究用于发现(689例新发病例、1850例非病例),独立队列研究用于验证(262例新发病例、2549例非病例)。

主要发现

  • 从47种血清生物标志物中通过L1惩罚(lasso)Cox模型选出白介素-1受体拮抗剂、胰岛素样生长因子结合蛋白2、可溶性E-选择素、核心蛋白聚糖、脂联素和高密度脂蛋白胆固醇为最相关标志物。
  • 同时加入六种标志物在发现集显著改善预测性能:C指数(95%CI)提升0.053(0.039-0.066),无类别净重分类指数(cfNRI,95%CI)为67.4%(57.3%-79.5%)。
  • 在验证集中同样显著改善:C指数提升0.034(0.019-0.053),cfNRI为48.4%(35.6%-60.8%)。
  • 在GDRSadapted模型联合HbA1c基础上加入六种标志物,两项研究均观察到显著改善。

临床怎么用

  • 对于接受非侵入性临床风险评估(如GDRSadapted)或临床模型联合HbA1c评估的个体,可考虑检测这六种生物标志物以进一步细化2型糖尿病风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Improved strategies to identify persons at high risk of type 2 diabetes are important to target costly preventive efforts to those who will benefit most. OBJECTIVE: This work aimed to assess whether novel biomarkers improve the prediction of type 2 diabetes beyond noninvasive standard clinical risk factors alone or in combination with glycated hemoglobin A1c (HbA1c). METHODS: We used a population-based case-cohort study for discovery (689 incident cases and 1850 noncases) and an independent cohort study (262 incident cases, 2549 noncases) for validation. An L1-penalized (lasso) Cox model was used to select the most predictive set among 47 serum biomarkers from multiple etiological pathways. All variables available from the noninvasive German Diabetes Risk Score (GDRSadapted) were forced into the models. The C index and the category-free net reclassification index (cfNRI) were used to evaluate the predictive performance of the selected biomarkers beyond the GDRSadapted model (plus HbA1c). RESULTS: Interleukin-1 receptor antagonist, insulin-like growth factor binding protein 2, soluble E-selectin, decorin, adiponectin, and high-density lipoprotein cholesterol were selected as the most relevant biomarkers. The simultaneous addition of these 6 biomarkers significantly improved the predictive performance both in the discovery (C index [95% CI], 0.053 [0.039-0.066]; cfNRI [95% CI], 67.4% [57.3%-79.5%]) and the validation study (0.034 [0.019-0.053]; 48.4% [35.6%-60.8%]). Significant improvements by these biomarkers were also seen on top of the GDRSadapted model plus HbA1c in both studies. CONCLUSION: The addition of 6 biomarkers significantly improved the prediction of type 2 diabetes when added to a noninvasive clinical model or to a clinical model plus HbA1c.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Thorand B, Zierer A, Büyüközkan M, et al. A Panel of 6 Biomarkers Significantly Improves the Prediction of Type 2 Diabetes in the MONICA/KORA Study Population. J Clin Endocrinol Metab. 2021. PMID: 33382400. doi:10.1210/clinem/dgaa953

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。